<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of bone health in preterm infants</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of bone health in preterm infants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of bone health in preterm infants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Garcia-Prats, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>All neonates, and especially premature infants, are at risk for osteopenia and rickets. As a result, they must have adequate intake of calcium, phosphorus, and vitamin D to ensure adequate mineralization for bone structural integrity and growth. Premature infants require particularly high dietary concentrations of these nutrients, with additional measures guided by close monitoring.</p><p>For term neonates, either human milk or formula (when taken in adequate volume for age) provides adequate intake of calcium and phosphorus. In this group, management of neonatal bone heath is primarily focused on vitamin D supplementation, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Prevention in the perinatal period and in infants'</a>.)</p><p>The management of bone health in preterm infants will be reviewed here. The general approach to nutrition in premature infants is discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants"</a> and  <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p class="headingAnchor" id="H89952645"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span></p><p class="headingAnchor" id="H4041524714"><span class="h2">Factors affecting neonatal bone health</span><span class="headingEndMark"> — </span>Premature infants are at high risk for osteopenia and rickets for several reasons:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid growth</strong> – Because of their rapid growth, preterm infants have high requirements for calcium and phosphorus, which are critical components for bone structural integrity and growth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shortened gestation</strong> – Preterm delivery disrupts the normal intrauterine accretion of calcium and phosphorus. The third trimester is the period of maximal placental transfer of these nutrients, reflecting the rapid skeletal growth of the fetus. Placental transfer reaches a peak accretion rate at 32 to 36 weeks gestation, with calcium transferred at 100 to 130 mg/kg of fetal weight per day and phosphorus transferred at 60 to 70 mg/kg of fetal weight per day [<a href="#rid1">1-4</a>]. As a result, the requirements of calcium and phosphorus increase with decreasing gestational age to compensate for the loss of accretion of these minerals and extremely low birth weight infants (birth weights below 1000 g) or those born before 27 weeks gestation are at particularly high risk for rickets [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intestinal absorption</strong> – In healthy preterm infants, calcium absorption is generally 50 to 60 percent from human milk and phosphorus absorption approximately 80 to 90 percent [<a href="#rid3">3,5-7</a>]. Absorption from infant formulas is slightly lower, depending on the formula composition [<a href="#rid8">8</a>]. These proportions are similar across a broad range of calcium intakes [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1">Absorption of calcium and phosphorus from the small intestine is by both active transport (transcellular) and passive diffusion (paracellular). For the first few weeks after preterm birth, most of the mineral absorption appears to be passive, based on limited data [<a href="#rid10">10</a>]. Thereafter, active transport, which requires vitamin D, becomes more important. Absorption of calcium and phosphorus is affected positively by postnatal age and vitamin D level and also varies with the dietary calcium:phosphorus ratio as well as dietary intake of lactose and fat [<a href="#rid6">6</a>]. [<a href="#rid3">3,5-7</a>]</p><p class="bulletIndent1">Neonates with underlying disease may have additional impediments to absorbing these nutrients. This includes infants with short bowel syndrome (intestinal failure) [<a href="#rid11">11</a>] and those requiring certain medications that interfere with absorption, such as glucocorticoids (which inhibit intestinal transfer of calcium), <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, and <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>, which may indirectly inhibit calcium absorption by interfering with vitamin D metabolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal excretion and absorption</strong> – Regulation of renal absorption and excretion is important for calcium and phosphorus balance. One important homeostatic mechanism is the secretion of parathyroid hormone in response to low calcium, resulting in reduced urinary calcium excretion. Under normal circumstances, nearly all filtered calcium is reabsorbed in the renal tubule.</p><p></p><p class="bulletIndent1">In the neonate, there are two main causes of hypercalciuria, which may lead to calcium depletion:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Loop diuretics enhance calcium excretion, which may result in nephrocalcinosis. In contrast, thiazide diuretics stimulate calcium absorption and reduce urinary calcium excretion. (See  <a class="medical medical_review" href="/z/d/html/6125.html" rel="external">"Nephrocalcinosis in neonates", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Phosphorus deficiency enhances calcium renal excretion, leading to hypercalciuria and resulting in ongoing calcium loss and potential calcium depletion [<a href="#rid8">8,12</a>]. Treatment with phosphorus will correct the phosphorus deficiency and hypercalciuria, but calcium should also be given since infants are depleted of both calcium and phosphorus.</p><p></p><p class="headingAnchor" id="H53280184"><span class="h2">Risk factors for rickets</span><span class="headingEndMark"> — </span>Very low birth weight (VLBW) infants (birth weight &lt;1500 g) and especially extremely low birth weight infants (birth weights &lt;1000 g) or those born before 27 weeks gestation are at risk for developing rickets [<a href="#rid3">3,13,14</a>]. Rickets in premature infants is primarily caused by inadequate calcium and phosphorus intake and absorption rather than vitamin D deficiency. This mechanism is reflected in the risk factors for neonatal rickets, which include  (<a class="graphic graphic_table graphicRef90619" href="/z/d/graphic/90619.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prematurity and VLBW (&lt;1500 g)</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal growth restriction, especially infants with birth weight &lt;3<sup>rd</sup> percentile for gestational age (see  <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Long-term parenteral nutrition (&gt;4 weeks)</p><p class="bulletIndent1"><span class="glyph">●</span>Bronchopulmonary dysplasia treated with loop diuretics and/or fluid restriction</p><p class="bulletIndent1"><span class="glyph">●</span>Long-term postnatal corticosteroid use</p><p class="bulletIndent1"><span class="glyph">●</span>History of necrotizing enterocolitis or other diseases causing intestinal failure, especially in patients who undergo surgical intervention</p><p class="bulletIndent1"><span class="glyph">●</span>Feeds that do not have high mineral content (eg, due to poor tolerance of fortified feeds)</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic or endocrine disorders, including severe cholestasis or renal disease</p><p></p><p class="headingAnchor" id="H2054874646"><span class="h2">Incidence of neonatal rickets</span><span class="headingEndMark"> — </span>The incidence of neonatal rickets is declining with the use of diets with high mineral content. (See <a class="local">'Fortification of feeds'</a> below.)</p><p>The incidence of rickets increases with decreasing birth weight. In a registry study from Sweden, rickets developed in 2 percent of infants born &lt;32 weeks gestation or &lt;1500 g birth weight and 0.1 percent of those born between 32 and 36 weeks gestation [<a href="#rid15">15</a>]. In a separate study of infants with birth weight &lt;1000 g, 15 percent developed rickets despite management with fortified feeds [<a href="#rid16">16</a>]. Incidence is also increased in infants with fetal growth restriction or necrotizing enterocolitis.</p><p class="headingAnchor" id="H3447716136"><span class="h1">OVERVIEW OF MANAGEMENT</span><span class="headingEndMark"> — </span>Management of bone health in preterm infants is focused on preventing rickets and encompasses:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing adequate calcium and phosphorus intake to promote normal bone growth. Nutritional support during the birth hospitalization and post-discharge must account for the loss of intrauterine accretion of these nutrients, their bioavailability in enterally fed infants, and ongoing losses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin D supplementation (minor role).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory monitoring to assess bone health, with the goal to detect and correct any mineral deficiency before the infant develops radiographic signs of rickets.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants who develop rickets, provision of supplemental calcium and phosphorus to repair bone mineralization.</p><p></p><p class="headingAnchor" id="H89953225"><span class="h1">INITIAL MANAGEMENT (INPATIENT)</span></p><p class="headingAnchor" id="H3389289030"><span class="h2">Parenteral nutrition</span><span class="headingEndMark"> — </span>Mineral accretion is inadequate in very low birth weight (VLBW) infants who are treated with total parenteral nutrition for more than two weeks [<a href="#rid17">17</a>]. This is related, in part, to the need to limit mineral concentrations because of their solubility in parenteral nutrition solutions. However, calcium and phosphorus concentrations should be maximized to improve mineral retention. (See  <a class="medical medical_review" href="/z/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants", section on 'Calcium and phosphate'</a>.)</p><p>Infants who receive parenteral nutrition for more than four weeks may have developed a mineral deficit that requires oral or enteral supplementation with calcium and phosphorus once feeds are established, in addition to the requirements outlined below. Therefore, these infants should have laboratory monitoring for bone health even if they are not VLBW. (See <a class="local">'Laboratory monitoring'</a> below.)</p><p class="headingAnchor" id="H89954021"><span class="h2">Enteral nutrition</span><span class="headingEndMark"> — </span>Unfortified human milk, parenteral nutrition, and formulas designed for term infants do not contain enough calcium and phosphorus to meet the needs for bone mineralization in preterm infants. As a result, the use of these diets without fortification limits bone growth and increases the risk for osteopenia, rickets, and bone fractures.</p><p class="headingAnchor" id="H2420815098"><span class="h3">Calcium and phosphorus requirements</span><span class="headingEndMark"> — </span>The appropriate enteral intake for calcium and phosphorus is based on estimates of optimal daily bone deposition, bioavailability and absorption of these nutrients, and nutrient losses. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p>We suggest the following intake in enteral feeds for VLBW infants (birth weight below 1500 g), consistent with guidance from the American Academy of Pediatrics [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium – 150 to 220 mg/kg/day</p><p class="bulletIndent1"><span class="glyph">●</span>Phosphorus – 75 to 140 mg/kg/day</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium:phosphorus ratio – Approximately 1.5 to 1.7 (mg/mg, or mass ratio), although the ideal range has not been clearly established [<a href="#rid3">3,18,19</a>]</p><p></p><p>Other organizations recommend somewhat lower targets for mineral intake:</p><p class="bulletIndent1"><span class="glyph">●</span>European guidelines recommend enteral intake of calcium 120 to 140 mg/kg/day and phosphorus 65 to 90 mg/kg/day [<a href="#rid20">20</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>An international consensus group recommends calcium 120 to 200 mg/kg/day and phosphorus 60 to 140 mg/kg/day [<a href="#rid21">21</a>]</p><p></p><p>The variance among these recommendations reflects different reviews of the limited data related to providing safe intake while ensuring adequate bone mineralization. As evidenced by the ranges provided by these recommendations, no single value for calcium intake can be considered as correct. There is no convincing evidence that the differences between these guidelines lead to clinically significant benefits or risks [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H820766764"><span class="h3">Vitamin D requirements</span><span class="headingEndMark"> — </span>Most authorities recommend vitamin D supplementation for preterm infants beginning in the neonatal period, although the benefit of supplements during the first month of life has not been established. For infants fed human milk, we begin vitamin D supplements when the infant is tolerating enteral feeds. For formula-fed infants, the formula provides sufficient vitamin D.</p><p>We suggest the following target intake, consistent with recommendations from the American Academy of Pediatrics [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For infants &lt;1500 g body weight, initial target is 5 to 10 micrograms (200 to 400 international units) daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the infant reaches ≥1500 g and is tolerating full enteral nutrition, increase vitamin D to 10 micrograms (400 international units); this is also the recommended vitamin intake for term infants</p><p></p><p>Other targets for enteral vitamin D intake are recommended by other groups:</p><p class="bulletIndent1"><span class="glyph">●</span>European guidelines suggest a higher vitamin D intake of 20 to 25 micrograms (800 to 1000 international units) daily during hospitalization or the first months of life [<a href="#rid20">20</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An international consensus group recommends intake of vitamin D between 10 and 25 micrograms (400 and 1000 international units) daily for preterm infants [<a href="#rid21">21</a>]</p><p></p><p>These guidelines were designed to achieve serum concentrations considered "sufficient" in older infants and children (usually defined as 25-hydroxyvitamin D ≥20 ng/mL), but they do <strong>not</strong> recommend routine laboratory testing of serum 25-hydroxyvitamin D in this population [<a href="#rid9">9</a>]. The variation in these recommendations reflects the uncertainty about the role of vitamin D for intestinal absorption of calcium in preterm infants. In particular, in preterm infants during the first month of life, calcium absorption appears to be primarily a passive process via a paracellular route and is not vitamin D dependent, based on limited data [<a href="#rid10">10</a>]. Although vitamin D concentrations are typically lower in preterm compared with term infants, data are limited on the relationship between vitamin D intake and serum 25-hydroxyvitamin D in preterm infants. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p>These targets are supported by limited evidence from clinical trials in preterm infants, which suggests that vitamin D intakes between 10 and 20 micrograms (400 to 800 international units) typically achieve 25-hydroxyvitamin D concentrations &gt;20 ng/mL [<a href="#rid22">22-25</a>]. However, the studies did not identify substantial differences in clinical outcomes across the range of vitamin D intakes, including markers of bone health (mean total-body bone mineral content and density as well as serum alkaline phosphatase activity [<a href="#rid23">23</a>]) or respiratory outcomes in extremely preterm infants [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H89953536"><span class="h3">Fortification of feeds</span><span class="headingEndMark"> — </span>For all infants with birth weights &lt;1500 g, we recommend fortifying feeds with calcium and phosphorus. We also routinely use multinutrient-fortified feeds for infants up to 2000 g birth weight. For infants with birth weight between 1500 and 2000 g, the primary benefits of fortified feeds are for growth since rickets is uncommon in this population.</p><p>Fortification can be accomplished by adding a human milk fortifier (HMF) to expressed human milk or by using a formula designed for preterm infants; either strategy supplies the necessary high mineral content in addition to supplemental energy (calories) and protein [<a href="#rid3">3,17</a>]. The recommendations for these products are based on weight rather than gestational age because infants with intrauterine growth restriction (also referred to as small for gestational age) also have impaired bone mineralization. (See  <a class="medical medical_review" href="/z/d/html/5050.html" rel="external">"Human milk feeding and fortification of human milk for premature infants", section on 'Fortification of human milk'</a>.)</p><p>Full enteral feedings of 150 to 160 mL/kg/day of fortified human milk or preterm formula provide estimated intakes of calcium of 150 to 220 mg/kg/day, phosphorus of 90 to 140 mg/kg/day, and vitamin D of 7.5 to 10 micrograms (300 to 400 international units) daily, which meet the recommended intake for these neonates  (<a class="graphic graphic_table graphicRef90621" href="/z/d/graphic/90621.html" rel="external">table 2</a>) [<a href="#rid3">3</a>]. In contrast, unfortified human milk provides insufficient intakes of these nutrients: approximately calcium 40 mg/kg/day, phosphorus 20 mg/kg/day, and negligible amounts of vitamin D. (See  <a class="medical medical_review" href="/z/d/html/5050.html" rel="external">"Human milk feeding and fortification of human milk for premature infants", section on 'Indications and fortifier types'</a> and  <a class="medical medical_review" href="/z/d/html/5047.html" rel="external">"Nutritional composition of human milk and preterm formula for the premature infant", section on 'Calcium and phosphorus'</a>.)</p><p>Unfortified human milk and formula designed for term infants have insufficient calcium and phosphorus concentrations to achieve optimal intake for bone mineralization in early preterm infants [<a href="#rid26">26,27</a>]. Use of fortified human milk or preterm formula improves mineral retention and bone mineral content compared with unfortified feeds  (<a class="graphic graphic_table graphicRef90620" href="/z/d/graphic/90620.html" rel="external">table 3</a>) and reduces the risk of rickets [<a href="#rid28">28</a>]. While clinical trial data on calcium and phosphorus supplementation in preterm infants are extremely limited [<a href="#rid29">29,30</a>], the available observational data suggest that use of fortified human milk or preterm formula substantially reduces the risk of rickets in VLBW infants. In older studies carried out prior to the routine practice of fortifying feeds in preterm infants, reported rates of rickets in VLBW infants ranged from 30 to 50 percent [<a href="#rid31">31-33</a>]. By contrast, reported rates of rickets among VLBW infants managed with fortified feeds in the modern era are substantially lower, ranging from 10 to 15 percent [<a href="#rid16">16,34-36</a>]. Although other improvements in neonatal care and nutrition may have contributed to reduced rates of rickets between the two eras, it is unlikely to fully explain the difference. Further support comes from several small trials and observational studies in which mineral supplementation was associated with improved radiographic and laboratory indices of bone mineralization and had no significant adverse effects [<a href="#rid37">37-41</a>]. (See  <a class="medical medical_review" href="/z/d/html/5047.html" rel="external">"Nutritional composition of human milk and preterm formula for the premature infant", section on 'Calcium and phosphorus'</a>.)</p><p class="headingAnchor" id="H28254018"><span class="h2">Physical stimulation</span><span class="headingEndMark"> — </span>It has been proposed that lack of physical activity contributes to poor bone health in preterm infants. Data from several small trials suggest possible short-term benefits of a neonatal physical therapy program on weight gain and bone mineralization in preterm infants, but the evidence is insufficient to understand the potential benefits or risks [<a href="#rid42">42</a>]. The therapy typically consists of passive range of motion and joint compression exercises performed for 5 to 15 minutes daily [<a href="#rid43">43</a>]. Many programs, including ours, now have physical therapists working with preterm infants on a regular basis, although these efforts are not specifically directed towards bone health.</p><p class="headingAnchor" id="H89954002"><span class="h2">Laboratory monitoring</span><span class="headingEndMark"> — </span>Because preterm infants are at risk for rickets, all VLBW infants (birth weight &lt;1500 g) should have laboratory monitoring throughout the birth hospitalization to detect any evidence of bone-related abnormalities [<a href="#rid3">3</a>].</p><p>Our suggested approach depends on risk factors  (<a class="graphic graphic_algorithm graphicRef131352" href="/z/d/graphic/131352.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Infants with VLBW or other risk factors – Measure serum phosphorus and alkaline phosphatase activity beginning four weeks after birth and repeated every two weeks thereafter until discharge. Other risk factors include prolonged parenteral nutrition or prolonged postnatal corticosteroids, regardless of birth weight  (<a class="graphic graphic_table graphicRef90619" href="/z/d/graphic/90619.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants with short bowel syndrome or other malabsorptive syndromes – In addition to the above for alkaline phosphatase and phosphorus, measure serum vitamin D concentrations, inorganic phosphorus, and magnesium as parenteral nutrition is weaned and periodically thereafter. (See  <a class="medical medical_review" href="/z/d/html/5886.html" rel="external">"Chronic complications of short bowel syndrome in children", section on 'Metabolic bone disease and rickets'</a>.)</p><p></p><p>We do not use parathyroid hormone levels to detect patients at risk for bone disease. A small study suggested that serum parathyroid hormone can be used as a marker of severe metabolic bone disease [<a href="#rid44">44</a>]. However, this is insufficient evidence to establish a benefit of this testing and such testing would add considerable cost to routine evaluations.</p><p class="headingAnchor" id="H2179844780"><span class="h2">Interpretation and next steps</span><span class="headingEndMark"> — </span>Next steps depend on the laboratory results and trend  (<a class="graphic graphic_algorithm graphicRef131352" href="/z/d/graphic/131352.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal pattern of alkaline phosphatase activity</strong> – VLBW infants without metabolic bone disease typically have alkaline phosphatase activity values that rise at four to six weeks after birth and peak at 400 to 800 international units/L and then decrease by 8 to 10 weeks as the infant completes the transition to enteral feeds. Monitoring can be discontinued once stable values are demonstrated on full enteral feeds (eg, once the serum alkaline phosphatase activity has peaked and is declining to &lt;500 to 600 international units/L, with serum phosphorus ≥4 mg/dL). (See <a class="local">'Infants with no evidence of bone disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated alkaline phosphatase activity</strong> – Alkaline phosphatase activity ≥1000 international units/L suggests the possibility of rickets [<a href="#rid16">16</a>]. In these patients, we obtain radiographs of the wrist and/or knees to confirm the diagnosis of rickets. (See <a class="local">'Infants with rickets'</a> below and  <a class="medical medical_review" href="/z/d/html/5856.html" rel="external">"Overview of rickets in children", section on 'Laboratory findings'</a>.)</p><p></p><p class="bulletIndent1">Infants with intermediate elevations of alkaline phosphatase activity (eg, &gt;800 international units/L) are at risk for rickets and should be monitored. If the alkaline phosphatase activity is rising or exceeds 1000 international units/L, we perform radiographic evaluation for rickets. If the alkaline phosphatase activity is stable, we repeat this test every two weeks until it is clearly declining.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low phosphorus</strong> – Many infants with metabolic bone disease have a low serum phosphorus in addition to elevated alkaline phosphatase activity. Both laboratory abnormalities are markers for mineral insufficiency and should improve with standard mineral supplementation.</p><p></p><p class="bulletIndent1">Other infants have a persistent low phosphorus (&lt;4 mg/dL) but normal patterns of alkaline phosphatase activity. This combination of findings is usually associated with normal bone health, in which the low phosphorus is likely primarily caused by rapid growth and indicates a need for additional phosphorus for nonbone tissue growth. In this case, oral phosphorus should be given in addition to the usual fortification strategy until the serum phosphorus increases to &gt;5 mg/dL.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUBSEQUENT MANAGEMENT</span></p><p class="headingAnchor" id="H452142631"><span class="h2">Infants with no evidence of bone disease</span><span class="headingEndMark"> — </span>For infants who reach a body weight of 2000 g and have no laboratory evidence of metabolic bone disease (serum alkaline phosphatase &lt;800 international units/L and falling, with serum phosphorus ≥4 mg/dL) or ongoing risk factors for rickets  (<a class="graphic graphic_table graphicRef90619" href="/z/d/graphic/90619.html" rel="external">table 1</a>), the mineral content of the feeds can be decreased  (<a class="graphic graphic_algorithm graphicRef131352" href="/z/d/graphic/131352.html" rel="external">algorithm 1</a>). The transition to feeds with lower mineral content is typically done quickly (eg, over three days) and during the final week before hospital discharge.</p><p>The strategy for changing to a transitional diet with lower mineral content depends on the infant's mode of feeding:</p><p class="bulletIndent1"><span class="glyph">●</span>If the infant transitions to direct breastfeeding, his or her mineral intake naturally decreases as the proportion of direct breastfeeding increases. Some of these infants may require supplemental feeds to maintain adequate intakes of energy and other nutrients. (See  <a class="medical medical_review" href="/z/d/html/5035.html" rel="external">"Breastfeeding the preterm infant", section on 'Transition to full breastfeeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the infant is fed expressed breast milk by bottle, the amount of human milk fortifier (HMF) can be reduced. Alternatively, the HMF can be stopped and a preterm formula used for a few feedings each day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the infant is formula fed, he or she can change from preterm formula to a "transitional" formula.</p><p></p><p>After the dietary transition and hospital discharge, we continue the transitional diet, as outlined above, for at least a few weeks. The decision to transition to an unfortified diet is driven primarily by growth considerations and is discussed separately (see  <a class="medical medical_review" href="/z/d/html/5003.html" rel="external">"Growth management in preterm infants"</a>). We repeat laboratory monitoring only if there are residual risk factors or other concerns for rickets, such as relatively high alkaline phosphatase activity at discharge. Vitamin D supplements should be continued for breastfed infants (10 micrograms [400 international units] daily). (See <a class="local">'Vitamin D requirements'</a> above.)</p><p class="headingAnchor" id="H86500317"><span class="h2">Infants with ongoing risk for rickets</span><span class="headingEndMark"> — </span>Ongoing risk for infants is indicated by either  (<a class="graphic graphic_algorithm graphicRef131352" href="/z/d/graphic/131352.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory evidence of metabolic bone disease – Serum alkaline phosphatase activity persistently ≥800 international units/L with or without serum phosphorus &lt;4 mg/dL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing risk factors – Such as prolonged parenteral nutrition, fluid restriction, or malabsorptive disease  (<a class="graphic graphic_table graphicRef90619" href="/z/d/graphic/90619.html" rel="external">table 1</a>)</p><p></p><p>For these infants, we optimize the high-mineral diet (fortified human milk or preterm infant formula) and repeat the laboratory tests approximately every two weeks.</p><p>The target for calcium and phosphorus intake depends on the level of concern and the infant's mode of feeding. As an example, an infant with mildly abnormal serum alkaline phosphatase activity who is directly breastfeeding may be supplemented by giving two to four bottle feeds daily of fortified human milk or preterm formula.</p><p>The next steps for this group of infants depend upon the trend in alkaline phosphatase activity:</p><p class="bulletIndent1"><span class="glyph">●</span>Rising trend – Perform radiographic evaluation for rickets</p><p class="bulletIndent1"><span class="glyph">●</span>Stable – Continue high-mineral diet, with monthly laboratory monitoring</p><p class="bulletIndent1"><span class="glyph">●</span>Declining trend – Transition to lower-mineral diet, as described above; recheck alkaline phosphatase activity several weeks after transition if there are ongoing concerns or risk factors</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Infants with rickets</span></p><p class="headingAnchor" id="H424036"><span class="h3">Clinical features and diagnosis</span><span class="headingEndMark"> — </span>Rickets in premature infants typically develops between 3 and 12 weeks of age. The condition is not usually clinically apparent and is identified on routine laboratory screening by elevated alkaline phosphatase activity (&gt;1000 international units/L), with or without low serum phosphorus (&lt;4 mg/dL).</p><p>The diagnosis is confirmed based on radiographs of the knee or wrist. Diagnostic findings are widening of the epiphyseal plate and loss of definition of the zone of provisional calcification at the epiphyseal/metaphyseal interface, similar to those for older infants with nutritional rickets  (<a class="graphic graphic_diagnosticimage graphicRef90646" href="/z/d/graphic/90646.html" rel="external">image 1</a>).</p><p>In severe cases, rickets may present with fractures  (<a class="graphic graphic_diagnosticimage graphicRef90647" href="/z/d/graphic/90647.html" rel="external">image 2</a>). This was illustrated in a multicenter retrospective study of chest radiographs of infants born at &lt;37 weeks gestation, in which rib fractures were identified in 26 of 1446 infants (1.8 percent) [<a href="#rid45">45</a>]. The median age at the time of detection was 14 weeks, and the median-corrected gestational age was 39 weeks. Most infants had multiple fractures, and 40 percent of the fractures were located posteriorly. Rib fractures were attributed to osteopenia of prematurity in two-thirds of the patients (n = 17 patients).</p><p class="headingAnchor" id="H17"><span class="h3">Initial management</span><span class="headingEndMark"> — </span>Management of neonatal rickets involves  (<a class="graphic graphic_algorithm graphicRef131352" href="/z/d/graphic/131352.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium and phosphorus replacement</strong> – For enterally fed infants, rickets is treated by providing supplemental calcium and phosphorus, typically delivered by feeding fortified human milk or premature formula  (<a class="graphic graphic_table graphicRef90621" href="/z/d/graphic/90621.html" rel="external">table 2</a>) [<a href="#rid28">28,46</a>]. If the infant develops rickets despite fortified feeds, we review the intake and feeding strategy to ensure calcium and phosphorus intake at the high end of the recommended ranges. (See <a class="local">'Calcium and phosphorus requirements'</a> above and <a class="local">'Fortification of feeds'</a> above.)</p><p></p><p class="bulletIndent1">In some infants, fluid limitations or feeding intolerance may limit the use of recommended amounts of HMF or preterm formulas. These infants may require additional calcium and phosphorus supplements, which we implement as follows [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elemental calcium is initiated at 20 mg/kg/day and increased as tolerated to a maximum dose of 70 to 80 mg/kg/day. These doses refer to supplemental dosing and do not include the calcium content from breast milk or formula. In our practice, we typically use <a class="drug drug_pediatric" data-topicid="12897" href="/z/d/drug information/12897.html" rel="external">calcium glubionate</a> solution; however, if this is not available, <a class="drug drug_pediatric" data-topicid="12569" href="/z/d/drug information/12569.html" rel="external">calcium carbonate</a> or other formulations may be used.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elemental phosphorus is initiated at a dose of 10 to 20 mg/kg/day and increased as tolerated to a maximum dose of 40 to 50 mg/kg/day. In our practice, we typically give oral doses of the intravenous formulation of either sodium or <a class="drug drug_pediatric" data-topicid="12985" href="/z/d/drug information/12985.html" rel="external">potassium phosphate</a>. If these are not available, we use an oral solution of sodium and potassium phosphate (Neutra-Phos).</p><p></p><p class="bulletIndent1">For infants on parenteral nutrition, provide the maximum allowable parenteral mineral concentrations in their parenteral nutrition formulation. Calcium and phosphate content in parenteral nutrition is limited by concerns about precipitation, as described separately (see  <a class="medical medical_review" href="/z/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants", section on 'Calcium and phosphate'</a>). These infants typically require subsequent oral supplementation once enteral feeds are established.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D</strong> – Rickets in preterm infants is primarily a disorder of calcium and phosphorus deficiency and generally is not mediated by vitamin D deficiency. In our institution, we typically increase vitamin D to 20 micrograms (800 international units) daily for infants with confirmed rickets to ensure vitamin D sufficiency while proceeding with other interventions. (See <a class="local">'Vitamin D requirements'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fracture prevention and management</strong> – Premature infants with rickets are at high risk for fractures, which may occur accidentally during routine care by the medical team or family. Caregivers should be advised to handle the infant gently.</p><p></p><p class="bulletIndent1">If fractures occur, they are managed conservatively with supplemental minerals and vitamin D rather than surgical intervention. Because fractures are common in infants with neonatal rickets, further evaluation for genetic causes of bone fractures such as osteogenesis imperfecta is generally unnecessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants with cholestasis or renal disease</strong> – Infants with severe cholestasis or other chronic illnesses may need prolonged supplementation with high doses of calcium, phosphorus, and vitamin D. If cholestasis or renal disease is severe, oral vitamin D may not be adequate to form active 1,25-dihydroxyvitamin D and vitamin D may need to be administered directly as the active form <a class="drug drug_pediatric" data-topicid="13107" href="/z/d/drug information/13107.html" rel="external">calcitriol</a> (1,25-dihydroxyvitamin D), with appropriate monitoring of serum calcium to avoid hypercalcemia.</p><p></p><p class="headingAnchor" id="H4006063273"><span class="h3">Monitoring and subsequent management</span></p><p class="bulletIndent1">After initiating calcium and phosphorus supplementation, as outlined above, the next steps are:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measure phosphorus and alkaline phosphatase activity every two weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Obtain follow-up radiographs after approximately six weeks</p><p></p><p>Most infants treated with increased calcium and phosphorus have improved radiographic findings after several weeks, and serum phosphorus concentration and alkaline phosphatase activity normalize.</p><p>Once biochemical values have improved and radiographs show signs of healing, supplemental calcium and phosphorus may be weaned over two to four weeks and ultimately stopped. No specific laboratory criteria have been defined, but we typically stop the mineral supplements when the serum alkaline phosphatase value is &lt;500 to 600 international units/L and trending downward, unless the infant has malabsorptive disease or other reasons for a high mineral requirement.</p><p class="headingAnchor" id="H465091153"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111345.html" rel="external">"Society guideline links: Breastfeeding and infant nutrition"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111342.html" rel="external">"Society guideline links: Pediatric bone health"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/143917.html" rel="external">"Society guideline links: Nutrition support (parenteral and enteral nutrition) for neonates including preterm infants"</a>.)</p><p class="headingAnchor" id="H644081"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Premature infants are at risk for osteopenia and rickets. Infants with very low birth weight (VLBW; &lt;1500 g) have particularly high requirements for calcium and phosphorus because of their rapid growth and to compensate for the loss of accretion of these nutrients during the third trimester of pregnancy. (See <a class="local">'Factors affecting neonatal bone health'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The main risk factor for rickets in VLBW infants is insufficient intake of calcium and phosphorus. Other risk factors include long-term parenteral nutrition, use of loop diuretics, and fluid restriction  (<a class="graphic graphic_table graphicRef90619" href="/z/d/graphic/90619.html" rel="external">table 1</a>). (See <a class="local">'Risk factors for rickets'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of rickets in premature infants focuses on providing adequate calcium and phosphorus intake. Unfortified human milk, parenteral nutrition, and formulas designed for term infants do not contain enough calcium and phosphorus to fully meet the needs for normal bone mineralization in these infants. In general, rickets in preterm infants is not mediated by vitamin D deficiency. (See <a class="local">'Enteral nutrition'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For all VLBW infants, we recommend fortifying feeds with calcium and phosphorus (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Mineral fortification substantially reduces the risk of rickets and fractures and has no adverse effects within the recommended range for intake. This can be accomplished by adding a commercial multinutrient human milk fortifier (HMF) to human milk or by feeding a preterm infant formula  (<a class="graphic graphic_table graphicRef90621" href="/z/d/graphic/90621.html" rel="external">table 2</a>). Either of these strategies also provides supplemental energy and protein, which have other benefits. Most institutions provide fortified feeds for infants 1500 to 2000 g primarily to provide additional protein and energy for growth rather than specifically for rickets prevention. (See <a class="local">'Fortification of feeds'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For preterm infants, we suggest vitamin D supplementation beginning during the birth hospitalization rather than deferring supplementation until after hospital discharge (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The approach is generally similar to guidelines for term infants. Vitamin D supplements in recommended ranges are safe and may have benefits on bone health in some preterm infants or after the neonatal period, based on very limited data. For VLBW infants, we target vitamin D intake between 5 and 10 micrograms (200 and 400 international units) daily and increase to 10 micrograms (400 international units) daily when the infant reaches 1500 g of body weight and is tolerating full enteral nutrition. (See <a class="local">'Vitamin D requirements'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all VLBW infants, we suggest routine laboratory testing with alkaline phosphatase activity and phosphorus. We initiate testing at four weeks of age and repeat the tests every two weeks until the infant is on full enteral feeds and the alkaline phosphatase activity is decreasing  (<a class="graphic graphic_algorithm graphicRef131352" href="/z/d/graphic/131352.html" rel="external">algorithm 1</a>). (See <a class="local">'Laboratory monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>This testing can be discontinued once the serum alkaline phosphatase activity has peaked and then declined to less than approximately 500 international units/L and the infant is on appropriate enteral nutrition. These infants can also transition to feeds with lower mineral content (eg, unfortified human milk or transitional formula). For healthy infants, this transition is typically done during the final week before hospital discharge. Vitamin D supplementation should be continued. (See <a class="local">'Infants with no evidence of bone disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If serum alkaline phosphatase activity rises to ≥1000 international units/L at any point (or ≥800 international units/L with an increasing trend), the infant should be evaluated for rickets by performing a radiograph of the wrist and/or knee. (See <a class="local">'Infants with rickets'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants with intermediate results on laboratory testing (eg, alkaline phosphatase activity 800 to 1000 international units/L and stable or serum phosphorus &lt;4 mg/dL) or those with additional risk factors for rickets may require prolonged dietary fortification and laboratory monitoring, including after hospital discharge. (See <a class="local">'Infants with ongoing risk for rickets'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rickets is suggested by serum alkaline phosphatase activity ≥1000 international units/L, and the diagnosis is confirmed by wrist and/or knee radiographs  (<a class="graphic graphic_algorithm graphicRef131352" href="/z/d/graphic/131352.html" rel="external">algorithm 1</a>). For preterm infants with rickets, we suggest increasing the calcium and phosphorus intake (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We target calcium and phosphorus at the upper end of the recommended range, which can generally be provided by feeds of fortified human milk or formula designed for premature infants. In addition, we suggest adequate vitamin D supplementation (10 to 20 micrograms [400 to 800 international units] daily) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, most neonatal rickets is not mediated by vitamin D and the requirement in preterm infants is not well established. (See <a class="local">'Infants with rickets'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Widdowson EM. Importance of nutrition in development, with special reference to feeding low-birth-weight infants. In: Meeting Nutritional Goals for Low-Birth-Weight Infants, Sauls HS, Bachhuber WL, Lewis LA (Eds), Ross Laboratories, Columbus 1982. p.4.</li><li><a class="nounderline abstract_t">Ziegler EE, O'Donnell AM, Nelson SE, Fomon SJ. Body composition of the reference fetus. Growth 1976; 40:329.</a></li><li><a class="nounderline abstract_t">Abrams SA, Committee on Nutrition. Calcium and vitamin d requirements of enterally fed preterm infants. Pediatrics 2013; 131:e1676.</a></li><li><a class="nounderline abstract_t">Ellis KJ, Shypailo RJ, Schanler RJ. Body composition of the preterm infant. Ann Hum Biol 1994; 21:533.</a></li><li><a class="nounderline abstract_t">Schanler RJ, Rifka M. Calcium, phosphorus and magnesium needs for the low-birth-weight infant. Acta Paediatr Suppl 1994; 405:111.</a></li><li><a class="nounderline abstract_t">Abrams SA, Esteban NV, Vieira NE, Yergey AL. Dual tracer stable isotopic assessment of calcium absorption and endogenous fecal excretion in low birth weight infants. Pediatr Res 1991; 29:615.</a></li><li><a class="nounderline abstract_t">Hicks PD, Rogers SP, Hawthorne KM, et al. Calcium absorption in very low birth weight infants with and without bronchopulmonary dysplasia. J Pediatr 2011; 158:885.</a></li><li><a class="nounderline abstract_t">Rowe J, Rowe D, Horak E, et al. Hypophosphatemia and hypercalciuria in small premature infants fed human milk: evidence for inadequate dietary phosphorus. J Pediatr 1984; 104:112.</a></li><li><a class="nounderline abstract_t">Abrams SA. Vitamin D in Preterm and Full-Term Infants. Ann Nutr Metab 2020; 76 Suppl 2:6.</a></li><li><a class="nounderline abstract_t">Bronner F, Salle BL, Putet G, et al. Net calcium absorption in premature infants: results of 103 metabolic balance studies. Am J Clin Nutr 1992; 56:1037.</a></li><li><a class="nounderline abstract_t">Mutanen A, Mäkitie O, Pakarinen MP. Risk of metabolic bone disease is increased both during and after weaning off parenteral nutrition in pediatric intestinal failure. Horm Res Paediatr 2013; 79:227.</a></li><li><a class="nounderline abstract_t">Senterre J, Salle B. Renal aspects of calcium and phosphorus metabolism in preterm infants. Biol Neonate 1988; 53:220.</a></li><li><a class="nounderline abstract_t">Backström MC, Kuusela AL, Mäki R. Metabolic bone disease of prematurity. Ann Med 1996; 28:275.</a></li><li><a class="nounderline abstract_t">Rigo J, De Curtis M, Pieltain C, et al. Bone mineral metabolism in the micropremie. Clin Perinatol 2000; 27:147.</a></li><li><a class="nounderline abstract_t">Högberg U, Winbo J, Fellman V. Population-based register study of children born in Sweden from 1997 to 2014 showed an increase in rickets during infancy. Acta Paediatr 2019; 108:2034.</a></li><li><a class="nounderline abstract_t">Mitchell SM, Rogers SP, Hicks PD, et al. High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional support. BMC Pediatr 2009; 9:47.</a></li><li><a class="nounderline abstract_t">Nehra D, Carlson SJ, Fallon EM, et al. A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for metabolic bone disease. JPEN J Parenter Enteral Nutr 2013; 37:570.</a></li><li><a class="nounderline abstract_t">Rowe JC, Goetz CA, Carey DE, Horak E. Achievement of in utero retention of calcium and phosphorus accompanied by high calcium excretion in very low birth weight infants fed a fortified formula. J Pediatr 1987; 110:581.</a></li><li><a class="nounderline abstract_t">Koletzko B, Goulet O, Hunt J, et al. 1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr 2005; 41 Suppl 2:S1.</a></li><li><a class="nounderline abstract_t">Agostoni C, Buonocore G, Carnielli VP, et al. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 2010; 50:85.</a></li><li class="breakAll">Nutritional Care of Preterm Infants: Scientific Basis and Practical Guidelines, Koletzko B, Poindexter B, Uauy R (Eds), Karger, 2014. Vol 110.</li><li><a class="nounderline abstract_t">Fort P, Salas AA, Nicola T, et al. A Comparison of 3 Vitamin D Dosing Regimens in Extremely Preterm Infants: A Randomized Controlled Trial. J Pediatr 2016; 174:132.</a></li><li><a class="nounderline abstract_t">Natarajan CK, Sankar MJ, Agarwal R, et al. Trial of daily vitamin D supplementation in preterm infants. Pediatrics 2014; 133:e628.</a></li><li><a class="nounderline abstract_t">Anderson-Berry A, Thoene M, Wagner J, et al. Randomized trial of two doses of vitamin D3 in preterm infants &lt;32 weeks: Dose impact on achieving desired serum 25(OH)D3 in a NICU population. PLoS One 2017; 12:e0185950.</a></li><li><a class="nounderline abstract_t">Kumar M, Shaikh S, Sinha B, et al. Enteral Vitamin D Supplementation in Preterm or Low Birth Weight Infants: A Systematic Review and Meta-analysis. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Atkinson SA, Radde IC, Anderson GH. Macromineral balances in premature infants fed their own mothers' milk or formula. J Pediatr 1983; 102:99.</a></li><li><a class="nounderline abstract_t">Faienza MF, D'Amato E, Natale MP, et al. Metabolic Bone Disease of Prematurity: Diagnosis and Management. Front Pediatr 2019; 7:143.</a></li><li><a class="nounderline abstract_t">Schanler RJ, Abrams SA. Postnatal attainment of intrauterine macromineral accretion rates in low birth weight infants fed fortified human milk. J Pediatr 1995; 126:441.</a></li><li><a class="nounderline abstract_t">Harding JE, Wilson J, Brown J. Calcium and phosphorus supplementation of human milk for preterm infants. Cochrane Database Syst Rev 2017; 2:CD003310.</a></li><li><a class="nounderline abstract_t">Kumar M, Chowdhury R, Sinha B, et al. Enteral Calcium or Phosphorus Supplementation in Preterm or Low Birth Weight Infants: a Systematic Review and Meta-analysis. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Lyon AJ, McIntosh N, Wheeler K, Williams JE. Radiological rickets in extremely low birthweight infants. Pediatr Radiol 1987; 17:56.</a></li><li><a class="nounderline abstract_t">Koo WW, Sherman R, Succop P, et al. Sequential bone mineral content in small preterm infants with and without fractures and rickets. J Bone Miner Res 1988; 3:193.</a></li><li><a class="nounderline abstract_t">Dabezies EJ, Warren PD. Fractures in very low birth weight infants with rickets. Clin Orthop Relat Res 1997; :233.</a></li><li><a class="nounderline abstract_t">Avila-Alvarez A, Urisarri A, Fuentes-Carballal J, et al. Metabolic Bone Disease of Prematurity: Risk Factors and Associated Short-Term Outcomes. Nutrients 2020; 12.</a></li><li><a class="nounderline abstract_t">Figueras-Aloy J, Álvarez-Domínguez E, Pérez-Fernández JM, et al. Metabolic bone disease and bone mineral density in very preterm infants. J Pediatr 2014; 164:499.</a></li><li><a class="nounderline abstract_t">Viswanathan S, Khasawneh W, McNelis K, et al. Metabolic bone disease: a continued challenge in extremely low birth weight infants. JPEN J Parenter Enteral Nutr 2014; 38:982.</a></li><li><a class="nounderline abstract_t">Steichen JJ, Gratton TL, Tsang RC. Osteopenia of prematurity: the cause and possible treatment. J Pediatr 1980; 96:528.</a></li><li><a class="nounderline abstract_t">Lapillonne A, Salle BL, Glorieux FH, Claris O. Bone mineralization and growth are enhanced in preterm infants fed an isocaloric, nutrient-enriched preterm formula through term. Am J Clin Nutr 2004; 80:1595.</a></li><li><a class="nounderline abstract_t">Chan GM, Mileur L, Hansen JW. Effects of increased calcium and phosphorous formulas and human milk on bone mineralization in preterm infants. J Pediatr Gastroenterol Nutr 1986; 5:444.</a></li><li><a class="nounderline abstract_t">Schanler RJ, Garza C, Smith EO. Fortified mothers' milk for very low birth weight infants: results of macromineral balance studies. J Pediatr 1985; 107:767.</a></li><li><a class="nounderline abstract_t">Narbona E, Maldonado J, Ocete E, et al. Bone mineralization status measured by dual energy radiographic densitometry in preterm infants fed commercial formulas. Early Hum Dev 1998; 53 Suppl:S173.</a></li><li><a class="nounderline abstract_t">Schulzke SM, Kaempfen S, Trachsel D, Patole SK. Physical activity programs for promoting bone mineralization and growth in preterm infants. Cochrane Database Syst Rev 2014; :CD005387.</a></li><li><a class="nounderline abstract_t">Stalnaker KA, Poskey GA. Osteopenia of Prematurity: Does Physical Activity Improve Bone Mineralization in Preterm Infants? Neonatal Netw 2016; 35:95.</a></li><li><a class="nounderline abstract_t">Moreira A, Swischuk L, Malloy M, et al. Parathyroid hormone as a marker for metabolic bone disease of prematurity. J Perinatol 2014; 34:787.</a></li><li><a class="nounderline abstract_t">Lucas-Herald A, Butler S, Mactier H, et al. Prevalence and characteristics of rib fractures in ex-preterm infants. Pediatrics 2012; 130:1116.</a></li><li class="breakAll">Abrams SA. Enteral feeding of the preterm infant: An update of recent findings. In: Baillieres Clinical Paediatrics: Nutritional Support, Ryan S (Ed), Bailliere Tindall, London 1997. p.305.</li></ol></div><div id="topicVersionRevision">Topic 5056 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Widdowson EM. Importance of nutrition in development, with special reference to feeding low-birth-weight infants. In: Meeting Nutritional Goals for Low-Birth-Weight Infants, Sauls HS, Bachhuber WL, Lewis LA (Eds), Ross Laboratories, Columbus 1982. p.4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1010389" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Body composition of the reference fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23629620" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Calcium and vitamin d requirements of enterally fed preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840493" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Body composition of the preterm infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7734782" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Calcium, phosphorus and magnesium needs for the low-birth-weight infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1866219" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dual tracer stable isotopic assessment of calcium absorption and endogenous fecal excretion in low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21300373" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Calcium absorption in very low birth weight infants with and without bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6690655" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hypophosphatemia and hypercalciuria in small premature infants fed human milk: evidence for inadequate dietary phosphorus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33232955" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vitamin D in Preterm and Full-Term Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1307704" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Net calcium absorption in premature infants: results of 103 metabolic balance studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636002" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk of metabolic bone disease is increased both during and after weaning off parenteral nutrition in pediatric intestinal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3046668" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Renal aspects of calcium and phosphorus metabolism in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862679" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Metabolic bone disease of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690569" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bone mineral metabolism in the micropremie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31050835" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Population-based register study of children born in Sweden from 1997 to 2014 showed an increase in rickets during infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19640269" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23685349" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for metabolic bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3559809" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Achievement of in utero retention of calcium and phosphorus accompanied by high calcium excretion in very low birth weight infants fed a fortified formula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254497" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19881390" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19881390" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27079965" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A Comparison of 3 Vitamin D Dosing Regimens in Extremely Preterm Infants: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24515510" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Trial of daily vitamin D supplementation in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29016653" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized trial of two doses of vitamin D3 in preterm infants&lt;32 weeks: Dose impact on achieving desired serum 25(OH)D3 in a NICU population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35921678" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Enteral Vitamin D Supplementation in Preterm or Low Birth Weight Infants: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6848738" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Macromineral balances in premature infants fed their own mothers' milk or formula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31032241" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Metabolic Bone Disease of Prematurity: Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7869208" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Postnatal attainment of intrauterine macromineral accretion rates in low birth weight infants fed fortified human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28238222" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Calcium and phosphorus supplementation of human milk for preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35921668" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Enteral Calcium or Phosphorus Supplementation in Preterm or Low Birth Weight Infants: a Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3822583" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Radiological rickets in extremely low birthweight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3213615" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sequential bone mineral content in small preterm infants with and without fractures and rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9020223" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fractures in very low birth weight infants with rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33321828" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Metabolic Bone Disease of Prematurity: Risk Factors and Associated Short-Term Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24331689" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Metabolic bone disease and bone mineral density in very preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23963689" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Metabolic bone disease: a continued challenge in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7359255" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Osteopenia of prematurity: the cause and possible treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585774" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bone mineralization and growth are enhanced in preterm infants fed an isocaloric, nutrient-enriched preterm formula through term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3723265" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of increased calcium and phosphorous formulas and human milk on bone mineralization in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4056979" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fortified mothers' milk for very low birth weight infants: results of macromineral balance studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10102664" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bone mineralization status measured by dual energy radiographic densitometry in preterm infants fed commercial formulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24752440" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Physical activity programs for promoting bone mineralization and growth in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27052984" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Osteopenia of Prematurity: Does Physical Activity Improve Bone Mineralization in Preterm Infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24875407" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Parathyroid hormone as a marker for metabolic bone disease of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23166339" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence and characteristics of rib fractures in ex-preterm infants.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
